GURUFOCUS.COM » STOCK LIST » Financial Services » Insurance » Hubei Biocause Pharmaceutical Co Ltd (SZSE:000627) » Definitions » Shiller PE Ratio

Hubei Biocause Pharmaceutical Co (SZSE:000627) Shiller PE Ratio : 15.22 (As of May. 15, 2025)


View and export this data going back to 1996. Start your Free Trial

What is Hubei Biocause Pharmaceutical Co Shiller PE Ratio?

As of today (2025-05-15), Hubei Biocause Pharmaceutical Co's current share price is ¥2.74. Hubei Biocause Pharmaceutical Co's E10 for the quarter that ended in Sep. 2024 was ¥0.18. Hubei Biocause Pharmaceutical Co's Shiller PE Ratio for today is 15.22.

The historical rank and industry rank for Hubei Biocause Pharmaceutical Co's Shiller PE Ratio or its related term are showing as below:

SZSE:000627' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.72   Med: 33.76   Max: 1090
Current: 15.22

During the past years, Hubei Biocause Pharmaceutical Co's highest Shiller PE Ratio was 1090.00. The lowest was 9.72. And the median was 33.76.

SZSE:000627's Shiller PE Ratio is ranked worse than
55.77% of 355 companies
in the Insurance industry
Industry Median: 14.3 vs SZSE:000627: 15.22

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Hubei Biocause Pharmaceutical Co's adjusted earnings per share data for the three months ended in Sep. 2024 was ¥0.007. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is ¥0.18 for the trailing ten years ended in Sep. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Hubei Biocause Pharmaceutical Co Shiller PE Ratio Historical Data

The historical data trend for Hubei Biocause Pharmaceutical Co's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hubei Biocause Pharmaceutical Co Shiller PE Ratio Chart

Hubei Biocause Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 44.20 28.79 17.34 15.86 14.63

Hubei Biocause Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.75 14.63 14.01 10.20 21.05

Competitive Comparison of Hubei Biocause Pharmaceutical Co's Shiller PE Ratio

For the Insurance - Life subindustry, Hubei Biocause Pharmaceutical Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hubei Biocause Pharmaceutical Co's Shiller PE Ratio Distribution in the Insurance Industry

For the Insurance industry and Financial Services sector, Hubei Biocause Pharmaceutical Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Hubei Biocause Pharmaceutical Co's Shiller PE Ratio falls into.


;
;

Hubei Biocause Pharmaceutical Co Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Hubei Biocause Pharmaceutical Co's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=2.74/0.18
=15.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hubei Biocause Pharmaceutical Co's E10 for the quarter that ended in Sep. 2024 is calculated as:

For example, Hubei Biocause Pharmaceutical Co's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=0.007/115.7848*115.7848
=0.007

Current CPI (Sep. 2024) = 115.7848.

Hubei Biocause Pharmaceutical Co Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201412 -0.048 99.000 -0.056
201503 -0.015 99.900 -0.017
201506 -0.012 99.500 -0.014
201509 -0.014 100.500 -0.016
201512 0.221 100.600 0.254
201603 0.240 102.200 0.272
201606 -0.020 101.400 -0.023
201609 0.003 102.400 0.003
201612 0.226 102.600 0.255
201703 0.030 103.200 0.034
201706 0.120 103.100 0.135
201709 0.050 104.100 0.056
201712 0.100 104.500 0.111
201803 0.070 105.300 0.077
201806 0.100 104.900 0.110
201809 0.030 106.600 0.033
201812 0.070 106.500 0.076
201903 0.070 107.700 0.075
201906 0.080 107.700 0.086
201909 0.060 109.800 0.063
201912 0.150 111.200 0.156
202003 0.080 112.300 0.082
202006 0.030 110.400 0.031
202009 0.010 111.700 0.010
202012 0.004 111.500 0.004
202103 0.045 112.662 0.046
202106 0.019 111.769 0.020
202109 0.007 112.215 0.007
202112 0.029 113.108 0.030
202203 0.030 114.335 0.030
202206 0.006 114.558 0.006
202209 0.012 115.339 0.012
202212 0.012 115.116 0.012
202303 0.010 115.116 0.010
202306 -0.048 114.558 -0.049
202309 -0.005 115.339 -0.005
202312 -0.087 114.781 -0.088
202403 -0.018 115.227 -0.018
202406 -0.056 114.781 -0.056
202409 0.007 115.785 0.007

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Hubei Biocause Pharmaceutical Co  (SZSE:000627) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Hubei Biocause Pharmaceutical Co Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Hubei Biocause Pharmaceutical Co's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Hubei Biocause Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
2nd Floor, Building 1, No. 1 Tianshan Road, Guohua Huijin Center, Zhanghe New District, Hubei Province, Jingmen, CHN, 448000
Hubei Biocause Pharmaceutical Co Ltd is a China-based company engaged in life insurance, health insurance, accident insurance, and other life insurance businesses, medicine, and chemical businesses. The company generates its revenue in the form of premiums.
Executives
Jiang Hai Hua Independent director
Fu Yong Jin Directors, executives
Wu Shi Yan Supervisors

Hubei Biocause Pharmaceutical Co Headlines

No Headlines